


2Q 2017

APS JAPAN ALPHA FUND

APS Asset Management is a Singapore headquartered fund manager with research offices in China and Japan as well as a client servicing office in New York. The firm was founded in 1995 by its CIO, Wong Kok Hoi. The Fund seeks capital appreciation over a medium to long term market cycle by investing in stocks of companies listed on the Japan Stock Exchange.

PERFORMANCE OVERVIEW



Fund returns are cumulative and are gross of management and performance fees. The net returns are net of all fees and charges. Benchmark: TOPIX Index *Annualized returns are the average annual compounded returns. Inception Date: July 1, 2000.

	Fun	d (%)	Benchmark	Excess	(%)	
Period	Gross	Net	(%)	Gross	Net	
June 2017	0.75	0.75	1.15	-0.40	-0.41	
2Q 2017	9.48	8.74	5.68	3.80	3.06	
YTD 2017	20.55	18.79	10.18	10.37	8.61	
Annualized Retur	Annualized Returns*					
1-Year	23.11	21.60	18.13	4.98	3.46	
3-Year	8.11	6.92	4.80	3.30	2.11	
5-Year	11.62	10.54	8.25	3.37	2.29	
7-Year	9.93	8.68	6.05	3.87	2.63	
10-Year	4.31	3.20	-0.02	4.33	3.22	
Since Inception	2.96	2.05	-0.38	3.34	2.42	

PORTFOLIO ANALYSIS (AS % OF AUM)

TOP FIVE LARGEST HOLDINGS

Tsumura & Co	6.3
Ai Holdings Corporation	5.9
SCSK Corporation	5.4
Eiken Chemical	5.2
Open Door Incorporation	4.8

MARKET CAPITALIZATION

>USD 10 bil	20.4
USD 5 bil – USD 10 bil	7.3
USD 2 bil – USD 5 bil	21.0
USD 500 mn – USD 2 bil	26.7
<usd 500="" mn<="" th=""><th>19.8</th></usd>	19.8
Cash	4.9

SECTOR WEIGHTINGS

Information Technology	32.7
Industrials	22.2
Health Care	21.8
Consumer Discretionary	12.3
Consumer Staples	2.4
Real Estate	2.3
Materials	1.5
Cash	4.9

Source: APS, Bloomberg and Wilshire.



APS JAPAN ALPHA FUND

2Q 2017

INVESTMENT PERFORMANCE & NOTABLE DEVELOPMENTS

The APS Japan Alpha Fund gained +9.48% in the second quarter, outperforming the benchmark by 3.80 percentage points. YTD, the fund rose +20.55%, outperforming the benchmark by 10.37 percentage points.

In the 2nd quarter, we continued to exploit "perception gaps" between APS' and the market's assessment of specific stocks. We initiated positions in stocks such as Nihon Trim, where our rigorous research found that the stocks are trading far below their intrinsic value. On the other hand, we took profit on positions that reached our target price and we will continue to sell off stocks with narrowing "perception gaps". Our analyses are presented in greater detail below.

Tsumura, a major manufacturer of traditional Japanese medicine with 80% market share in Japan, was the biggest contributor to the fund's performance in the quarter. We believe that investors are beginning to take notice of the company as the industry has grown continuously thanks mainly to increasing awareness among physicians. At the same time, the overall prescription medicine market has struggled due to severe government price cuts and pressure from generic drugs. Also, Tsumura posted strong 4Q results with better-than-expected improvement in gross margin, which is an aspect investors have long been concerned about. The improvement was driven by more cost-effective sourcing of raw materials and by yen appreciation.

Digital Arts, a growing cyber security software company, was the second biggest contributor during the quarter. We increased the stock's weighting in April and the stock rose by +29% in May because investors are gaining confidence in the company's future prospects. Digital Arts' sales and operating profit grew +26% and +81% respectively in FY2016. Further growth catalysts will come from Digital Arts' expansion into the market for software protecting against external attacks. This segment is 5x larger than Digital Arts' current area of focus, which is software for internally originated attacks. We believe the company will continue to ride on the trend of structural demand for cyber security in Japan.

Ai Holdings was another major contributor during the quarter. The company is growing through aggressive M&As led by its visionary founder and CEO, Mr. Hideyoshi Sasaki. Ai Holdings has several high quality businesses such as surveillance cameras for apartments, cutting machines for consumers, instant card-issuing machines for banks, etc. We increased the stock's weighting in February as we believe it was trading at an attractive price given its intrinsic value, and indeed the stock price rebounded by +12% in March and a further +14% during the April-to-June quarter reflecting its strong fundamentals.

NuFlare Technology, a small cap, highly advanced semiconductor equipment maker, was a detractor in the April-to June quarter. We initiated a position in May, and the stock price declined slightly. Our investment thesis is predicated or the value of NuFlare's technology and its financial position. We believe the demand for electron single-beam mask writers will remain stable due to strengthening demand for semiconductor manufacturing equipment. NuFlare will also catch up with cutting-edge electron multi-beam machines from next year. In terms of financial position, the company has net cash of JPY 37 bn, equivalent to 48% of market cap. In addition, there is a possibility that Toshiba Group, which owns 65% of the shares, may sell the shares to improve its financial position if some leading semiconductor equipment makers offers a premium for this highly advanced company.

Fanuc was a detractor in the second quarter. The stock fell by -5.1% in the quarter mainly because the company released a weaker than expected profit forecast for FY2017 due to increasing R&D and manufacturing capacity which Fanuc has prioritized in pursuit of future growth. We believe the demand for computer numerical control (CNC) machines and robots will be strong, particularly in China and the U.S. We visited the company's factory at the foot of Mt. Fuji in April to gain a deeper understanding of the proposition "robot made by robot". We believe factory automation will be accelerated worldwide, and Fanuc should have a key competitive position as its CNC machine is the de facto standard.

Astellas was the third largest detractor in the quarter mainly because the market including sell-side analysts became pessimistic after Astellas reported that its biggest revenue generator, Xtandi, saw flat sales volume growth in the US. We believe that the drug's slowdown is already priced into the valuation of 14.4x PE, the lowest among the Japanese major



2O 2017

pharmas, while ROE is 16%, the highest among the same group. Astellas has a number of attractive pipelines including Roxadustat for the treatment of chronic kidney disease with potential peak sales of over \$1bn, which we believe is not reasonably reflected in the share price yet.

Strategy & Continued Research

We expect some volatility in the Japanese market due to several upcoming political events with geopolitical risk but APS will remain focused on fundamentals and valuation instead of on macro events with no material link to fundamentals. We like this type of volatility as it presents opportunities for us to initiate or increase positions in companies that are mispriced but have significant upside potential in the longer horizon based on our rigorous research. In addition, the Japanese market is in a significant stage of structural transformation, and we believe that we can find many growth companies.

Source: APS

PORTFOLIO ACTIVITY

Recent Buys

Nihon Trim manufactures and sells home water purifiers based on electrolyzed reduced-water systems. With a 65% market share, it is the largest player in this segment. The company's home water purifiers have grown by 5Y CAGR of +9.4% until FY 2015 due to improving awareness of water's role in health. However, the media negatively portrayed hydrogen water last summer and market sentiment towards the water purifying sector dimmed. Nihon Trim's sales and stock price declined although the company's products have no known harmful effects. Our discussion with its CEO confirmed that sales have bottomed out and even if sales continued to fall -10% this year, the company's intrinsic value would still be 15% above its market value. It has JPY 9.4 bn of net cash equivalent to 30% of market cap and continues to earn recurring cash flow from cartridge replacements. In addition, it has other healthcare businesses such as a hospital in China, water for dialysis, umbilical cord blood managing services, and a bottled water businesses in Indonesia. Profits from these operations are still small, but there is a huge upside if some of these businesses succeed.

JustSystems is a software development company renowned for the Japanese word processer "Ichitaro". In 2009 Keyence, a leading Japanese factory automation company, acquired a 40% stake of JustSystems and changed the management as well as sales and development strategies. Since then, JustSystems has had a remarkable turnaround and is profitable. We recently met its CEO, Kyoutaro Sekinada, who was responsible for the turnaround. The meeting gave us confidence that JustSystems will continue growing and improving its operating margin via the "Keyence way" i.e. develop customer-driven products in a timely fashion and leverage the existing customer base by selling them further products. In addition, a revised policy for public schools taking effect in 2020 will require a tablet for every student. JustSystems currently has 80% of the educational software market comprising 20,000 public schools; the company already has a foot in the door and will be a significant beneficiary of this policy. Since no sell-side analyst covers it, we believe there is a significant gap between its market and intrinsic value. As our DCF model shows more than +90% upside, we decided to invest in this stock.

As we mentioned earlier, we also initiated a position in **NuFlare Technology** in May.



Recent Sells

Seiko Epson is one of the largest manufacturers of inkjet printers. The company has recently entered into the copier market by leveraging its precision core technology. The market is expecting another success story along the lines of the big tank inkjet printer. However, we believe it is difficult to make profits from copiers in developed markets like Japan as price competition is intensifying. Therefore, we decided to take profit on this stock.

We exited our positions in **Toyota** and **Denso** as the challenges are mounting for large, traditional auto and parts manufacturers over the long term. Both competition and development costs are climbing but it will be difficult to pass the costs on to buyers. As electric vehicles and self-driving cars become part of the automobile landscape, the demand for car electronics is accelerating, and this has attracted many competitors into the auto supply chain including electronics, components, materials, systems integration, EMS, etc. Some of the new players came from slowing industries such as smart phones. At the same time, the spread of ride hailing services such as Uber can lead to decreasing car ownership and car sales volume. Declining volume will impact margins. Denso is attempting to grow via advanced assisted driver systems (ADAS) but this segment's contribution to profits is limited.

STATISTICAL PROPERTIES & RISK ANALYSIS

RETURNS	AVE MTHLY	ANNUALIZED
Since Inception	0.24%	2.96%
Last 60 mths	0.92%	11.62%
Last 36 mths	0.65%	8.11%
Last 12 mths	1.75%	23.11%

RISK	AVE MTHLY	ANNUALIZED
Since Inception	4.81%	16.68%
Last 60 mths	3.89%	13.48%
Last 36 mths	3.45%	11.96%
Last 12 mths	3.48%	12.05%

RELATIVE RATIOS	INDEX		
Information Ratio	0.35		
Up Capture	94%		
Down Capture	98%		

PORTFOLIO ANALYTICS	Fund	INDEX
Total Return	64.20%	-6.26%
Annualized Return	2.96%	-0.38%
Annualized Volatility	16.68%	16.18%
Annualized Sharpe Ratio*	0.26	0.06
Annualized Sortino Ratio*	0.26	-0.03
Annualized Alpha	3.57%	-
Beta	85.6%	-
Correlation	83%	-
Positive Months	111	109
Negative Months	93	95
Maximum Drawdown	-48.08%	-56.58%
Best Month	12.87%	14.41%
Worst Month	-14.67%	-13.92%

Index: Topix Index

Inception date: July 2000

Note: Fund performance is expressed in USD and is gross of management and performance fees.

All risk statistics are calculated from Inception to June 2017 unless otherwise specified.

*Assuming Bank of Japan Result Unsecured Overnight Call Rate as the risk-free rate (with a floor of 0.00%)



20 2017

APS JAPAN ALPHA FUND

FUND INFORMATION

Investment Manager Company APS Asset Management Pte Ltd		<u>Fund Details</u> Domicile	Dublin, Ireland		
Lead Portfolio Manager	Hiromitsu Kawakita	Structure	Open ended UCITS Unit Trust		
Inception Date	July 1, 2000				
Fund AUM	USD 33.96 mn				
Fund Base Currency	USD				
			Class A	Class B	Class C
NAV Price as at June 30th.	. 2017	Liquidity	Daily	Daily	Daily
Class A: USD 143.44 Class B: USD 140.25		Minimum Initial Subscription	USD100,000	USD1,000	€1,000
		Management Fee	0.75%	1.5%	1.5%
* There were no units in Class C as at June 30^{th} , 2017.		Performance Fee	15%	0%	0%
Bloomberg Code Class A: APSGJPG ID Class B: APSJPAB ID		Dealing Deadline	5pm Daily (Irish Time), 1 Business Day Preceding Dealing day		
		Subscription Fee	Up to 5%		
		Redemption Fee	Up to 3%		
<u>Client Services Contact In</u> New York Singapore E-mail	formation (1) 646 693 8530 (65) 6333-8600 cs@aps.com.sg	Benchmark Legal Adviser Auditor Manager Administrator	TOPIX Index A&L Goodbody Deloitte & Touche Northern Trust Fund Services (Ireland) Lt Northern Trust International Fund Administration Services (Ireland) Ltd		

Composite reports which have been prepared in compliance with the Global Investment Performance Standards (GIPS) are available upon request.

Registration No.: 1980-00835-G

IMPORTANT NOTICE: This publication is strictly for information and general circulation only and does not have regard to the specific objectives, financial situation and particular needs of any specific person. It is not, and should not be construed as, an offer, invitation to offer, solicitation, recommendation or commitment to enter into any dealing in securities and form of transaction. Nothing contained herein constitutes investment advice and should not be relied upon as such. APS is not carrying out any financial advisory services and not acting as any investor's and potential investor's financial adviser or in any fiduciary capacity in respect of any proposed or potential investment. Investors and potential advisers should seek independent advice from a financial advisor regarding the suitability of the Fund and securities mentioned before making any investment. In the event that the investor or potential investor chooses not to do so, he should consider carefully whether the Fund and securities are suitable for him in his financial circumstances. Past performance of the Fund, securities and the Investment Manager and any forecasts made or opinions expressed on the economy, stock market or economic trends of the markets are definitely not indicative of future or likely performance or any guarantee of returns. APS accepts no liability and responsibility, whatsoever, for any direct or consequential loss arising from any use of or reliance on this publication. Investments in units in the Fund ("Units") are subject to high degree of risks, including possible loss of entire principal amount invested. Investors and potential investors should carefully evaluate their financial circumstances, ability and willingness to take such risks. The value of the Units and the income accruing to the Units, if any, may fall or rise. Investments in the Units are not deposits or other obligations of or guaranteed or insured by APS. While APS believes the information for the publication, which is based on certain assumptions, conditions and facts available, to be reliable, this publication is provided on an "as is" and "as available" basis and subject to change, of whatsoever form and nature, at any time without notice. APS has not independently verified and does not make any representation or warranty as to the accuracy, adequacy, completeness, reasonableness or truth of the information. Investors and potential investors must read the Prospectus, which may be obtained from APS or any of its appointed distributors, to fully understand the investment objectives, all the terms, conditions and risks before deciding whether to subscribe for Units. Investors may only redeem Units in the manner set out in the Prospectus. Distribution of this publication to any person other than the recipient and its adviser(s) is unauthorized and any reproduction of the publication, in whole or in part, or the disclosure of any of the contents, in each such instance is strictly prohibited.